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Abstract
Introduction: Staphylococcus aureus is the most important pathogen in the development of surgical site infections (SSI).
Patients who carry S. aureus in the nose are at increased risk for the development of SSI in cardiothoracic and orthopedic
surgery. In these populations it has been shown that the risk for SSI can be substantially reduced by eradicating S. aureus
carriage. For vascular surgery the relation between nasal carriage and surgical site infections has not been clearly
investigated. For this reason we performed this study to analyze the relation between S. aureus nasal carriage and SSI in our
vascular surgery population.
Methods: A prospective cohort study was undertaken, including all patients undergoing vascular surgery between January
first 2010 and December 31th 2010. Before surgery patients were screened for S. aureus nasal carriage using a PCR
technique. The presence of SSI was recorded based on criteria of the CDC.
Results: Screening was performed in 224. Of those, 55 (24.5%) were positive, 159 (71.0%) were negative and 10 (4.5%) were
inconclusive. In the screened vascular population 4 S. aureus SSI occurred in the 55 carriers compared with 6 in 159 non-
carriers (p=0.24). A stratified analysis revealed a 10-fold increased risk in nasal carriers undergoing central reconstruction
surgery (3 S. aureus SSI in 20 procedures versus 1 in 65 procedures in non-carriers, p=0.039).
Discussion: In patients undergoing central reconstruction surgery nasals carriers are at increased risk for the development
of S. aureus SSI. These patients will probably benefit from perioperative treatment to eradicate nasal carriage.
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Introduction
Staphylococcus aureus nasal carriage increases a patient’s risk for
developing a health care-associated infection with this micro
organism, at least after cardiac surgery, orthopedic surgery and in
peritoneal dialysis. [1,2,3,4,5] Preoperative screening for nasal
carriage and subsequent treatment of carriers with mupirocin and
chlorhexidine reduces the risk for the development of hospital-
acquired S. aureus infections by 79% for deep-seated infections and
55% for superficial infections. [6] Consequently, the mean
duration of hospital stay is reduced in treated carriers by
approximately 2 days. A cost benefit analysis shows that the
strategy is cost-effective and saves lives. [7].
In vascular surgery little is known about the relation between
nasal carriage of S. aureus and surgical site infections (SSI).
For this reason we conducted a prospective analysis of S. aureus
nasal carriage in patients undergoing vascular surgery and the
occurrence of surgical site infections.
Methods
A prospective cohort study was performed on all patients who
underwent elective vascular surgery between January 1
st 2010 and
December 31th 2010 in the Amphia Hospital, Breda, The
Netherlands.
Operations included were; central reconstructions for both
abdominal aortic aneurysms and occlusive disease (endovascular
(EVAR) and open), peripheral bypass procedures (autologous and
PTFE), endarterectomies of the femoral and carotid artery,
embolectomies and Artero-venous access procedures.
Patients were screened on the day that they were admitted to
the vascular surgery department of the Amphia hospital in Breda.
Screening was performed using a dry, sterile swab, which was
rotated four times in each nostril. The swab was placed in saline
and centrifuged. Part of the sample was processed for polymerase
chain reaction (PCR) on the presence of S. aureus, and part was
inoculated onto a blood agar plate, to allow nasal and infecting
strains to be compared in case a surgical site infection did occur.
The GeneXpert MRSA/SA Assay (Cepheid, Sunnyvale, CA) is
a real-time PCR-based method, which identifies S. aureus and also
can differentiate whether a S. aureus is a Methicillin-susceptible
(MSSA) or Methicillin-resistant (MRSA). [8,9,10,11].
Patients were followed prospectively for the development of
Surgical site infections (SSI) which were defined according to the
criteria of the Centers for Disease Control. [12].
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pain around the wound within 30 days after the initial procedure,
and the presence of a positive culture, drainage of the wound, or
pus after a diagnostic puncture. When prosthetic material had
been used the follow up was extended up to one year. Infections
were differentiated between superficial, deep seated and organ
based infections.
Screening was performed as part of the infection control
strategy of the Amphia hospital using non-invasive sampling.
Approval of the medical ethical committee and informed consent
were not applicable.
A stratified analysis was performed for patients with central
vascular surgery, as we expected a possible difference for the
importance of nasal carriage between patients suffering from
peripheral arterial occlusive disease (PAOD) and patients suffering
from central diluting vascular disease.
Patients suffering from PAOD have a gradient of lower limb
ischemia, which ranges from impaired walking distance, due to
inappropriate blood flow to the lower limbs (intermittent
claudication), to critical limb ischemia. In those patients hypo
perfusion of the lower limbs often results in ischemia or even
ischemic ulcers. These ulcers may be colonized with pathogens,
which may be introduced into the surgical wound. This may alter
the role of nasal carriage as there is an additional source of S. aureus
in the patient.
Statistical analyses was performed with SPSS software v 19.0
(SPSS Inc., Chicago, IL, USA), the Fisher exact test was used to
determine significance.
A multivariate analysis was performed for evaluation of several
other known risk factors on the development of SSI’s. Chi-square
test was used to determine significance.
A P-value ,0,05 was considered significant.
Results
As shown in Table 1, 224 patients were included. There were a
total of 17 SSI’s, 13 of which were superficial, and 4 where deep
seated SSI’s. The PCR of nasal swabs showed that 159 (71.0%)
were negative for S. aureus, 55 (24.6%) were positive and 10 (4.5%)
were inconclusive because of inhibition of the amplification
reaction. In 214 patients with conclusive results, there were 16
surgical site infections, 10 of which were caused by S. aureus and 6
by other pathogens.
The incidence of surgical site infections in nasal carriers of
S. aureus is 4 out of 55 (7.3%), whereas the incidence in non-
carriers is 6 out of 159 (3.8%)(RR=1.9, 95%CI 0.5–7.5).
A stratified analysis was performed for central reconstruction
surgery, peripheral bypass surgery and other procedures as shown
in Table 2. In peripheral bypass surgery 2 S. aureus surgical site
infections occurred in patients who did not carry S. aureus (n=45)
and no infections in Patients who carried S. aureus (n=17)
(P.0.05).
In the central reconstruction surgery population, there was 1
surgical site infection in patients who did not carry S. aureus
(n=65), this SSI occurred after an aortoilliac bypass procedure
because of occlusive disease, and there were 3 infections with
S. aureus in Patients who carried S. aureus (n=20), 1 SSI after an
EVAR procedure, 1 SSI after open aneurysm repair and 1 after an
Table 1. Baseline and surgical characteristics and surgical site
infections caused by S. aureus.
Characteristics
N2 2 4
Sex, Male/Female (%) 171/53 (76.3/23.7)
Age mean (SD) 70 (10.1)
Type of Surgery N/(%)
Nu of SSI’s
(%)
Nu of S.
aureus SSI
(%)
Aortic open repair 52 (23) 6 (11) 3 (6)
Aortic endovascular repair 38 (17) 1 (3) 1 (3)
Femoral endarterectomy 34 (15) 3 (9) 3 (9)
Peripheral bypass surgery
Autologous bypass 42 (66) 2 (5) 1 (2)
PTFE bypass 22 (34) 4 (18) 1 (5)
AV access surgery 14 (6) 0 (0) 0 (0)
Peripheral embolectomy 4 (2) 1 (25) 1 (25)
Carotid endarterectomy 18 (8) 0 (0) 0 (0)
Total 224 (100) 17 (8) 10 (4)
doi:10.1371/journal.pone.0038127.t001
Table 2. Relation between S. aureus carriage and surgical site infections caused by S. aureus.
Surgery type
S. aureus SSI-rate (%) RR 95% CI P-value*
Central reconstructions (n=90)
Non-carriers (n=65) 1 (1,5)
Carriers (n=20) 3 (15) 9.8 1.1–88.6 0.039
Inconclusive (n=5)** 0
Other procedures (n=134)
Non-carriers (n=94) 5 (5)
Carriers (n=35) 1 (3) 0.5 0.1–4.4 0.48
Inconclusive (n=5)** 0
*Fisher’s exact test;
**Inconclusive screening results were not used for analyzation.
doi:10.1371/journal.pone.0038127.t002
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(RR=9.8, 95%CI 1.1–88.6, P=0.039).
A multivariate analysis including 3 other risk factors known
from the literature for the development of surgical site infections,
did not alter the effect of nasal carriage (Table 3).
Discussion
Our study shows that surgical site infections in vascular surgery
occur relatively frequent and that the majority (62%) are caused by
S. aureus. Especially the central reconstructions and the peripheral
bypass procedures have a relatively high incidence of surgical site
infections, compared to, for example, carotid endartectomies and
AV access procedures.
Overall there is no significant relation between nasal carriage of
S. aureus and the occurrence of surgical site infections. However, a
stratified analysis on patients who underwent abdominal aortic
surgery shows a significant association. The effect in this group is
comparable to what has been found previously in cardiothoracic
and orthopedic surgery. [1,2,3,5].
In other vascular procedures no significant effect was found.
The infections in this group mainly occurred in peripheral
procedures of patients with occlusive disease. Patients with
occlusive vascular disease cope with insufficient blood flow to at
least one of the, mostly lower, limbs. This insufficient blood flow is
often associated with ischemic disease, e.g. gangrene of non
healing ulcers. As this wounds can be infected or colonized prior to
surgery with a large scale of different pathogens, this could limit
the role of S. aureus nasal carriage. In our study no significant effect
after peripheral vascular surgery was found. However, for one
patient who was positive for S. aureus nasal carriage and who
developed a S. aureus SSI, accidently a sample of both the nasal
swab as well as a wound swab were available for typing. This
showed that the two trains were identical. Considering the small
number of patients and the frequent presence of wounds before
surgery we consider the role of nasal carriage in peripheral
vascular surgery unresolved.
All S. aureus strains were methicillin susceptible and no MRSA
was found which reflects the low rate of MRSA in Dutch hospitals.
Also all strains were mupirocin susceptible. Potentially adminis-
tration of mupirocin could reduce the risk of nasal carriage. [6] A
cost effectiveness analysis showed that treating every patient with
S. aureus eradication therapy, without screening for nasal carriage
is the most cost-effective way for preventing surgical site infections.
[7] However, as recent studies reported mupirocin resistant
MRSA strains [13,14], it should only be used in proven MSSA
and MRSA carriers to limit the risk for development of further
resistance.
Based on the results of this study we conclude that S. aureus
carriers who undergo central reconstructive surgery have a
significant higher risk for the development of SSI which can be
decreased by perioperative eradication of S. aureus in nasal carriers.
[6].
This is important because infection with S. aureus after aortic
reconstructions is related to severe complications and a high
mortality rate.
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